Richter Gedeon stock trades at EUR 33.71 with USD 6.8 billion value

Published on 10/09/2026 at 16:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The euro quote is EUR 33.71 on October 9, 2026. Richter Gedeon stock stands 0.87 percent above EUR 33.42, with USD 6.8 billion value and a 9.80 P/E.

Key points in brief

Richter Gedeon stock was trading at EUR 33.71 at Lang & Schwarz on October 9, 2026, up 0.87 percent from EUR 33.42.
The company had a USD 6.8 billion market capitalization and a 9.80 P/E on October 9, 2026.
Second-quarter 2026 revenue was HUF 241.4 billion, while net income fell 26.00 percent to HUF 38.3 billion.
The next reporting date is November 10, 2026.

Richter Gedeon, HU0000123096, Illustration mit AI erstellt.

Richter Gedeon (HU0000123096) was trading at EUR 33.71 at Lang & Schwarz on October 9, 2026 at 4:07 p.m. CEST, up 0.87 percent from the EUR 33.42 prior close. The quote puts the Hungarian pharmaceutical company at a USD 6.8 billion market value in the latest market snapshot.

Intraday quote stays measured

The Lang & Schwarz bid was EUR 33.38 and the ask was EUR 34.04 on October 9, 2026. The spread between the two prices was EUR 0.66, while the 0.87 percent move kept the session change below the 1.00 percent threshold used for a directional headline.

Second-quarter figures add contrast

Simply Wall St reports that Richter Gedeon's second-quarter 2026 revenue was HUF 241.4 billion, flat against the second quarter of 2025. Net income fell 26.00 percent year over year to HUF 38.3 billion, while the profit margin declined to 16.00 percent from 22.00 percent.

The earnings comparison matters for the valuation picture: the same source lists second-quarter 2026 earnings per share at HUF 209, down from HUF 283 in the second quarter of 2025. The figures show revenue stability alongside weaker earnings conversion.

Comparison with peers

Richter Gedeon: plus 0.87 percent, P/E 9.80, market capitalization USD 6.8 billion (October 9, 2026)

Teva (NYSE, USD): plus 6.62 percent, P/E 65.27, market capitalization USD 48.7 billion (October 9, 2026)

Novartis (NYSE, USD): plus 0.53 percent, P/E 21.97, market capitalization USD 273.5 billion (October 9, 2026)

Valuation and next reporting date

The price-to-earnings comparison places Richter Gedeon below the two selected pharmaceutical peers on the quoted instruments used for the comparison. Its 9.80 P/E is paired with a USD 6.8 billion market capitalization and a 0.05 dividend yield in the finance quote.

Simply Wall St lists November 10, 2026 as the next earnings date. The company investor page lists its first-half 2026 earnings presentation dated August 7, 2026.

Price and market position

Global Banking & Finance Review identifies Richter Gedeon as RICHTER.BD on Budapest under ISIN HU0000123096 and classifies it in Health Care. The listing currency is HUF, while the German investor view in this report uses the euro quote from Lang & Schwarz.

Richter Gedeon was trading at EUR 33.71 at Lang & Schwarz on October 9, 2026 at 4:07 p.m. CEST, plus 0.87 percent versus the EUR 33.42 prior close. The further course of trading is shown by the continuously updated real-time quote of Richter Gedeon stock.